medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 3

<< Back Next >>

Rev Invest Clin 2005; 57 (3)

Prolactin in the immunological system: synthesis and biological effects

Méndez I, Cariño C, Díaz L

Language: Spanish
References: 79
Page: 447-456
PDF size: 133.83 Kb.


ABSTRACT

Prolactin (PRL) is a 23 kDa protein hormone that is produced and secreted by the pituitary lactotrophs. Although PRL was initially regarded as an exclusive pituitary hormone, many nonpituitary tissues were later found to contain and produce this hormone. The most established extrapituitary sites that produce PRL are the decidua, the immune system, brain and endometrium. In the immune system, PRL acts as a cytokine where it plays an important role in human immune responses, including in autoimmune diseases. Here, we will discuss the regulation of PRL gene expression in human lymphocytes and review the functions of PRL made by the immune cells, including its involvement in autoimmunity.


REFERENCES

  1. Sricker PFG. Action du lobe anterieure de l’ypophyse sur la montée laitesse. Cr Soc Biol 1928; 99: 1978-80.

  2. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-68.

  3. Boulay JL, Paul WE. The interleukin-4-related lymphokines and their binding to hematopoietin receptors. J Biol Chem 1992; 267: 20525-8.

  4. Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 1994; 15: 627-49.

  5. Kelly PA, Djiane J, Katoh M, Ferland LH, Houdebine LM, Teyssot B, Dusanter-Fourt I. The interaction of prolactin with its receptors in target tissues and its mechanism of action. Recent Prog Horm Res 1984; 40: 379-439.

  6. Neill JM, Nagy GM. Prolactin secretion and its control. In: Knobil E NJ (Ed.). The Physiology of Reproduction. New York: Raven Press Ltd; 1994, p. 1833-60.

  7. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996; 17: 639-69.

  8. Hartmann DP, Holaday JW, Bernton EW. Inhibition of lymphocyte proliferation by antibodies to prolactin. FASEB J 1989; 3: 2194-202.

  9. Montgomery DW, Zukoski CF, Shah GN, Buckley AR, Pacholczyk T, Russell DH. Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity. Biochem Biophys Res Commun 1987; 145: 692-8.

  10. Wu H, Devi R, Malarkey WB. Expression and localization of prolactin messenger ribonucleic acid in the human immune system. Endocrinology 1996; 137: 349-53.

  11. DiMattia GE, Gellersen B, Bohnet HG, Friesen HG. A human B-lymphoblastoid cell line produces prolactin. Endocrinology 1988; 122: 2508-17.

  12. O’Neal KD, Montgomery DW, Truong TM, Yu-Lee LY. Prolactin gene expression in human thymocytes. Mol Cell Endocrinol 1992; 87: R19-23.

  13. Montgomery DW, Shen GK, Ulrich ED, Steiner LL, Parrish PR, Zukoski CF. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology 1992; 131: 3019-26.

  14. Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 1992; 6: 1023-31.

  15. Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, Kooijman R, Kutz L, Kelley KW, Malarkey WB. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992; 89: 7713-6.

  16. Gellersen B, DiMattia GE, Friesen HG, Bohnet HG. Prolactin (PRL) mRNA from human decidua differs from pituitary PRL mRNA but resembles the IM-9-P3 lymphoblast PRL transcript. Mol Cell Endocrinol 1989; 64: 127-30.

  17. DiMattia GE, Gellersen B, Duckworth ML, Friesen HG. Human prolactin gene expression. The use of an alternative noncoding exon in decidua and the IM-9-P3 lymphoblast cell line. J Biol Chem 1990; 265: 16412-21.

  18. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22: 724-63.

  19. Gellersen B, Kempf R, Telgmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994; 8: 356-73.

  20. Gellersen B, DiMattia GE, Friesen HG, Bohnet HG. Regulation of prolactin secretion in the human B-lymphoblastoid cell line IM-9-P3 by dexamethasone but not other regulators of pituitary prolactin secretion. Endocrinology 1989; 125: 2853-61.

  21. Reem GH, Ray DW, Davis JR. The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by cAMP. J Mol Endocrinol 1999; 22: 285-92.

  22. Hubina E, Nagy GM, Toth BE, Ivan G, Gorombey Z, Szabolcs I, Kovacs L, Goth MI. Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans. Endocrine 2002; 18: 215-9.

  23. Van De Weerdt C, Peers B, Belayew A, Martial JA, Muller M. Far upstream sequences regulate the human prolactin promoter transcription. Neuroendocrinology 2000; 71: 124-37.

  24. Berwaer M, Martial JA, Davis JR. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994; 8: 635-42.

  25. Telgmann R, Gellersen B. Marker genes of decidualization: activation of the decidual prolactin gene. Hum Reprod Update 1998; 4: 472-9.

  26. Larrea F, Martinez-Castillo A, Cabrera V, Alcocer-Varela J, Queipo G, Carino C, Alarcon-Segovia D. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab 1997; 82: 3664-9.

  27. Matera L, Cutufia M, Geuna M, Contarini M, Buttiglieri S, Galin S, Fazzari A, Cavaliere C. Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. J Neuroimmunol 1997; 79: 12-21.

  28. Gutierrez MA, Molina JF, Jara LJ, Cuellar ML, Garcia C, Gutierrez-Urena S, Gharavi A, Espinoza LR. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus 1995; 4: 348-52.

  29. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995; 16: 354-69.

  30. Leanos-Miranda A, Chavez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 866-75.

  31. Heffner LJ, Gramates LS, Yuan RW. A glycosylated prolactin species is covalently bound to immunoglobulin in human amniotic fluid. Biochem Biophys Res Commun 1989; 165: 299-305.

  32. Cohen H, Cohen O, Gagnon J. Serum prolactin-binding protein (PRL-BP) of human and rat are identified as IgG. C R Acad Sci III 1994; 317: 293-8.

  33. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934-8.

  34. Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ. Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 2003; 20: 111-4.

  35. Meng J, Tsai-Morris CH, Dufau ML. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Res 2004; 64: 5677-82.

  36. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of Langerhans. Endocrinology 2004; 145: 4162-75.

  37. Van Coppenolle F, Skryma R, Ouadid-Ahidouch H, Slomianny C, Roudbaraki M, Delcourt P, Dewailly E, Humez S, Crepin A, Gourdou I, Djiane J, Bonnal JL, Mauroy B, Prevarskaya N. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation. Biochem J 2004; 377: 569-78.

  38. Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA 1990; 87: 6460-4.

  39. Matera L, Cesano A, Bellone G, Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun 1992; 6: 409-17.

  40. Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen HG. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980; 51: 1058-63.

  41. Croze F, Walker A, Friesen HG. Stimulation of growth of Nb2 lymphoma cells by interleukin-2 in serum-free and serum-containing media. Mol Cell Endocrinol 1988; 55: 253-9.

  42. Buckley AR. Prolactin, a lymphocyte growth and survival factor. Lupus 2001; 10: 684-90.

  43. Cesano A, Oberholtzer E, Contarini M, Geuna M, Bellone G, Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology 1994; 28: 67-75.

  44. Carreno PC, Jimenez E, Sacedon R, Vicente A, Zapata AG. Prolactin stimulates maturation and function of rat thymic dendritic cells. J Neuroimmunol 2004; 153: 83-90.

  45. Matera L, Mori M, Galetto A. Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus 2001; 10: 728-34.

  46. Matera L, Galetto A, Geuna M, Vekemans K, Ricotti E, Contarini M, Moro F, Basso G. Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology 2000; 100: 29-36.

  47. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002; 57: 435-55.

  48. Dogusan Z, Hooghe R, Verdood P, Hooghe-Peters EL. Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 2001; 120: 58-66.

  49. Jabbour HN, Critchley HO, Yu-Lee LY, Boddy SC. Localization of interferon regulatory factor-1 (IRF-1) in nonpregnant human endometrium: expression of IRF-1 is up-regulated by prolactin during the secretory phase of the menstrual cycle. J Clin Endocrinol Metab 1999; 84: 4260-5.

  50. Viselli SM, Stanek EM, Mukherjee P, Hymer WC, Mastro AM. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology 1991; 129: 983-90.

  51. Mukherjee P, Mastro AM, Hymer WC. Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinology 1990; 126: 88-94.

  52. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann N Y Acad Sci 2000; 917: 505-13.

  53. Rincheval-Arnold A, Belair L, Cencic A, Djiane J. Up-regulation of polymeric immunoglobulin receptor mRNA in mammary epithelial cells by IFN-gamma. Mol Cell Endocrinol 2002; 194: 95-105.

  54. Welniak LA, Richards SM, Murphy WJ. Effects of prolactin on hematopoiesis. Lupus 2001; 10: 700-5.

  55. Tessier C, Prigent-Tessier A, Ferguson-Gottschall S, Gu Y, Gibori G. PRL antiapoptotic effect in the rat decidua involves the PI3K/protein kinase B-mediated inhibition of caspase-3 activity. Endocrinology 2001; 142: 4086-94.

  56. Goyeneche AA, Martinez IL, Deis RP, Gibori G, Telleria CM. In vivo hormonal environment leads to differential susceptibility of the corpus luteum to apoptosis in vitro. Biol Reprod 2003; 68: 2322-30.

  57. Fernandez ML, Iglesias MM, Biron VA, Wolfenstein_Todel C. Protective effect of prolactin and placental lactogen on NO-induced Nb2 lymphoma cell apoptosis. Arch Biochem Biophys 2003; 416: 249-56.

  58. Krishnan N, Thellin O, Buckley DJ, Horseman ND, Buckley AR. Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo. Endocrinology 2003; 144: 2102-10.

  59. Buckley AR, Buckley DJ. Prolactin regulation of apoptosis-associated gene expression in T cells. Ann NY Acad Sci 2000; 917: 522-33.

  60. Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004; 23: 1248-55.

  61. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554-61.

  62. Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 303: 222-6.

  63. Jimena P, Aguirre MA, Lopez-Curbelo A, de Andres M, Garcia-Courtay C, Cuadrado MJ. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998; 7: 383-6.

  64. Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, Espinoza LR. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 2003; 30: 2140-6.

  65. Daza L, Lavalle C, Duarte C, Huerta R, Moreno J. Lack of association between hyperprolactinemia and soluble IL-2 receptor levels in systemic lupus erythematosus. Lupus 2003; 12: 107-11.

  66. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus—association with disease activity. J Rheumatol 2001; 28: 2216-21.

  67. Mendez I, Alcocer-Varela J, Parra A, Lava-Zavala A, de la Cruz DA, Alarcon-Segovia D, Larrea F. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus 2004; 13: 45-53.

  68. Nagy E, Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology 1991; 128: 2776-84.

  69. McMurray RW. Prolactin in murine systemic lupus erythematosus. Lupus 2001; 10: 742-7.

  70. Hooghe R, Dogusan Z, Martens N, Velkeniers B, Hooghe-Peters EL. Effects of prolactin on signal transduction and gene expression: possible relevance for systemic lupus erythematosus. Lupus 2001; 10: 719-27.

  71. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000; 106: 1373-9.

  72. Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003; 111: 275-83.

  73. Peeva E, Venkatesh J, Michael D, Diamond B. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother 2004; 58: 310-9.

  74. Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 2001; 10: 676-83.

  75. Majumder B, Biswas R, Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer 2002; 97: 493-500.

  76. Matera L, Mori M, Geuna M, Buttiglieri S, Palestro G. Prolactin in autoimmunity and antitumor defense. J Neuroimmunol 2000; 109: 47-55.

  77. Kadioglu P, Acbay O, Demir G, Gazioglu N, Gundogdu S. The effect of prolactin and bromocriptine on human peripheral immune status. J Endocrinol Invest 2001; 24: 147-51.

  78. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112: 1211-22.

  79. Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1890-900.




2020     |     www.medigraphic.com